Zero Relapses in Three Years: The Cancer Vaccine That Won't Blink

Once injected, the MVA vector carries those tumor-specific sequences into the patient's immune cells. Those cells display the mutations like a wanted poster, teaching killer T cells exactly what to hunt. The result: CD8+ T cells (the immune system's assassins) and CD4+ helper T cells that can find and destroy any remaining cancer cells carrying those mutations.

In the Phase 1 data, 73.3% of patients mounted these neoantigen-specific T-cell responses. Patients responded to a median of three different neoantigens each. And here's the kicker: those responses persisted for more than a year after the last vaccination. The immune system didn't just learn the target; it remembered it.

Small Trial, Big Implications

Let's be honest about the limitations before we get too excited. Sixteen patients per arm is tiny. The study authors themselves acknowledged that the small number of patients and events "is insufficient to establish a statistically significant benefit." Kempen analyst Chiara Montironi called the longer follow-up a "robust dataset" supporting TG4050's relapse-prevention potential, but robust and definitive are two very different words.

Still, the signal is hard to ignore. Zero relapses versus three in the control arm, sustained over three years, with a clean safety profile and no unexpected findings. In the adjuvant setting (where you're treating patients who are technically cancer-free after surgery), safety matters enormously. You're asking healthy-feeling people to take a treatment that prevents something that might happen. If that treatment makes them miserable, they won't stick with it.

TG4050 passed that test with flying colors.

The Race It's Running In

Personalized cancer vaccines are having a moment, and TG4050 isn't the only horse on the track. Moderna and Merck's mRNA-4157 (V940) is the clear frontrunner in terms of clinical maturity. Their KEYNOTE-942 trial in high-risk melanoma showed 18-month relapse-free survival of 78.6% versus 62.2% for pembrolizumab alone, with a hazard ratio of 0.56. That program has already moved into a Phase 3 trial aiming to enroll over 1,000 patients, with results expected around 2029.

BioNTech is running its own individualized neoantigen platform (BNT122/autogene cevumeran) with strong immunogenicity data but no Phase 3 efficacy readout yet. Gritstone bio rounds out the competitive set but sits at an earlier stage.

What separates TG4050 is the platform. While Moderna and BioNTech use mRNA, Transgene uses an MVA viral vector. Different delivery truck, same destination. Whether one approach proves superior to the others is still anyone's guess, but TG4050's three-year data in a notoriously difficult cancer type gives the viral vector approach real credibility.

What Happens Next

Transgene isn't sitting on its hands. The Phase 2 portion of the trial finished patient randomization in April 2026, with 38 patients enrolled. The full Phase 1/2 program is expected to include roughly 80 patients across sites in the U.S. and France. Initial immunogenicity data from Phase 2 should arrive in the second half of 2026, with the big moment (two-year disease-free survival data) expected by the end of Q1 2028.

Behind the scenes, Transgene expanded its partnership with NEC through a 2026 license agreement for TG4050 development and commercialization using NEC's AI neoantigen prediction platform. They've also brought in BostonGene for tumor molecular profiling and sequencing support, which should speed up the process of building each patient's custom vaccine.

The Bottom Line

TG4050's three-year data won't change the standard of care tomorrow. The trial is too small for that, and the field knows it. But in the story of personalized cancer vaccines, this is a chapter worth reading carefully.

The concept has always been elegant: teach each patient's immune system to recognize their specific cancer. The hard part has been proving it works in humans, with durable responses, in a tough cancer, with manageable side effects. On all four counts, TG4050 just delivered.

Now comes the real test. Phase 2 data will tell us whether this holds up in a larger group. If it does, Transgene and NEC won't just have a promising vaccine; they'll have proof that AI-designed, patient-specific immunotherapy can keep cancer from coming back. And in HPV-negative head and neck cancer, where options are scarce and outcomes are grim, that would be something worth celebrating.

The Pill That Could Let Celiac Patients Eat Bread Again

Teva's experimental antibody just aced a mid-stage celiac disease trial, posting the best data anyone has seen in the IL-15 space. With zero approved targeted therapies and a market approaching $1 billion, the race to deliver the first real celiac drug is officially on.